Panome Bio will expand clinical access to its multiomics services through TD2 Oncology, moving beyond preclinical oncology use into clinical cancer research. The contract research organizations said the expanded agreement adds metabolomics, exposomics, proteomics and transcriptomics across blood and tissue sample types. The deal builds on an earlier relationship where TD2 already bundled Panome services for preclinical studies. Under the new terms, TD2 will offer customers access for clinical applications, aiming to strengthen translational work that links multi-layer biomarker profiling to therapeutic response. Panome framed the partnership as a way to connect biology across stages of development, pairing TD2’s translational and clinical oncology capabilities with deeper multiomics profiling. For biotech sponsors, broader multiomics availability through established CRO channels can shorten time-to-insight for mechanism-of-action questions and trial biomarker strategies.